临床靶向外显子组测序联合全基因组拷贝数分析:203例儿童脑肿瘤的精准医学分析
本研究为机构范围内前瞻性临床研究,采用靶向外显子测序平台OncoPanel和全基因组阵列比较基因组杂交OncoCopy对203例儿童脑肿瘤进行基因组分析。OncoPanel在56%的患者中发现了临床相关变异,OncoPanel与OncoCopy联合在89%(17/19)的髓母细胞瘤中识别出亚组特异性变异,表明联合多重基因组检测可为儿童脑肿瘤的临床评估提供有效的精准医学方法。
要点
- OncoPanel在56%的儿童脑肿瘤患者中检出临床相关变异,包括44个癌症突变和20个重排。
- 检测到MYB-QKI、MYBL1、BRAF和FGFR1重排,BRAF变异可指导靶向抑制剂的使用。
- OncoPanel与OncoCopy联合在89%(17/19)的髓母细胞瘤中识别出亚组特异性变异。
核心结论
- OncoPanel与OncoCopy联合多重基因组检测可识别关键的诊断、预后和治疗相关变异,是儿童脑肿瘤临床评估的有效精准医学方法。
研究设计与样本
- Profile为机构范围内前瞻性临床研究计划,采用靶向测序识别肿瘤可靶向变异。
- OncoPanel为靶向外显子测序平台,包含300个癌症相关基因,用于评估单核苷酸变异和重排/插入缺失。
- OncoCopy为临床全基因组阵列比较基因组杂交(aCGH)检测,用于评估拷贝数变异和重排断点。
- 共分析203例儿童脑肿瘤的癌症基因组,涵盖各组织学亚型;其中117例经OncoPanel分析,146例经OncoCopy分析,60例同时接受两种方法检测。
主要发现
- OncoPanel在56%的患者中检出临床相关变异,包括44个癌症突变和20个重排。
- 检出BRAF变异,可指导靶向抑制剂的使用;同时检测到MYB-QKI、MYBL1、BRAF和FGFR1重排。
- 拷贝数谱在不同组织学亚型间存在差异,OncoPanel与OncoCopy联合在89%(17/19)的髓母细胞瘤中识别出亚组特异性变异。
关键数值与推荐
- 变异按临床意义分为1-4级,其中1级变异具有明确的临床效用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical genomics platforms are needed to identify targetable alterations, but implementation of these technologies and best practices in routine clinical pediatric oncology practice are not yet well established. METHODS: Profile is an institution-wide prospective clinical research initiative that uses targeted sequencing to identify targetable alterations in tumors. OncoPanel, a multiplexed targeted exome-sequencing platform that includes 300 cancer-causing genes, was used to assess single nucleotide variants and rearrangements/indels. Alterations were annotated (Tiers 1-4) based on clinical significance, with Tier 1 alterations having well-established clinical utility. OncoCopy, a clinical genome-wide array comparative genomic hybridization (aCGH) assay, was also performed to evaluate copy number alterations and better define rearrangement breakpoints. RESULTS: Cancer genomes of 203 pediatric brain tumors were profiled across histological subtypes, including 117 samples analyzed by OncoPanel, 146 by OncoCopy, and 60 tumors subjected to both methodologies. OncoPanel revealed clinically relevant alterations in 56% of patients (44 cancer mutations and 20 rearrangements), including BRAF alterations that directed the use of targeted inhibitors. Rearrangements in MYB-QKI, MYBL1, BRAF, and FGFR1 were also detected. Furthermore, while copy number profiles differed across histologies, the combined use of OncoPanel and OncoCopy identified subgroup-specific alterations in 89% (17/19) of medulloblastomas. CONCLUSION: The combination of OncoPanel and OncoCopy multiplex genomic assays can identify critical diagnostic, prognostic, and treatment-relevant alterations and represents an effective precision medicine approach for clinical evaluation of pediatric brain tumors.
引用
- Ramkissoon SH, Bandopadhayay P, Hwang J, et al. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017. PMID: 28104717. doi:10.1093/neuonc/now294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。